Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Perilipin-3 (PLIN3) is a soluble cytosolic protein of the perilipin family that specifically localizes to the surface of intracellular lipid droplets (LDs), playing a key role in the biogenesis, stabilization, and metabolism of LDs[1][2][3]. Structurally, PLIN3 contains three domains: an N-terminal PAT domain (unique to perilipins), a central amphipathic helical repeat region, and a C-terminal four-helix bundle[1][2]. PLIN3, through its PAT domain, binds diacylglycerol (DAG) and is recruited to membrane locations enriched in lipogenic precursors (DAG and phosphatidic acid); this membrane association facilitates the nucleation and stabilization of nascent LDs at specific ER subdomains[1][2][3]. PLIN3 is not a receptor, enzyme, or canonical drug target, but rather acts as a membrane organizer and scaffold protein to coordinate neutral lipid clustering and LD protein recruitment, with crucial roles in early LD biogenesis and lipid compartmentalization[1][2][3]. PLIN3 has been referred to by several alternative names including TIP47 (tail-interacting protein of 47 kDa) and M6PRBP1 (mannose-6-phosphate receptor-binding protein 1), reflecting its historical identification in different biological contexts, such as in endosomal transport or placental protein studies. However, its central and best established role is as a cytoplasmic scaffold protein at the lipid droplet interface[1][2][3]. While not a direct therapeutic target, it is implicated in cellular lipid homeostasis, and altered expression or localization has been linked to certain pathologic conditions, including cancer and metabolic disease[2]. No approved drugs selectively target perilipin-3, and it is not currently used as a clinical biomarker. There are no known specific safety concerns or therapeutic challenges associated with modulating PLIN3, since selective pharmacological agents do not exist and the protein’s role is largely structural/metabolic in normal cells[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Perilipin-3 (PLIN3).